Factors associated with the discontinuation of evidence-based cardiovascular therapies in patients with stable coronary artery disease: A primary care perspective

European Journal of Preventive Cardiology

Volumn 16, Issue 1, 2009, Pages 34-38

  Mostaza, Jose M ^a   Lahoz, Carlos ^a   Martã­n Jadraque, Raquel ^a   Sanmartã­n, Miguel A ^b   Vicente, Ignacio ^a   Tranche, Salvador ^f   Taboada, Manuel ^c   Mantilla, Teresa ^d   Monteiro, Beatriz ^e   Sanchez Zamorano, Miguel Angel ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hospital Del Sureste   (Spain)

^c Centro de Salud de Fuencarral   (Spain)

^d CS Prosperidad   (Spain)

^e BRISTOL MYERS SQUIBB   (United States)

^f CS El Cristo   (Spain)

Author keywords

coronary artery disease; drugs; evidence based cardiovascular therapies; prevention; risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIMARY HEALTH CARE; SPAIN; ADULT; ADVERSE OUTCOME; ARTERY DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG WITHDRAWAL; HOSPITAL DISCHARGE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTILIPEMIC AGENTS; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; COMORBIDITY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PRIMARY HEALTH CARE; SPAIN;

EID: 65649118167     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32831a47f3     Document Type: Article

References (22)

1. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–1381.
2. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, De Long ER, et al Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203–212.
3. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745–749.
4. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner U, et al Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154: 1108–1115.
5. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177–186.
6. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 2002; 88: 159–162.
7. Wood D, EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
8. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008; 23: 115–121.
9. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, et al In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003; 163: 2576–2582.
10. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, et al Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117: 73–81.
11. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462–467.
12. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde D, et al Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005; 59: 564–573.
13. Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, et al National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006; 152: 454–458.
14. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185–191.
15. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145: 438–444.
16. Wald DS, Morton G, Walker K, losson N, Curzen NP. Long-term continuation on cardiovascular drug treatment in patients with coronary heart disease. Ann Pharmacother 2007; 41: 1644–1647.
17. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007; 115: 2128–2135.
18. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792–798.
19. Vohra RS, Gough MJ, Homer-Vanniasinkam S, Mavor AI, Howell S. Secondary prevention in patients with peripheral arterial disease: are we letting our patients down? Eur J Vasc Endovasc Surg 2007; 33: 190–191.
20. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769–1776.
21. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065–1070.
22. Madrid AH, Bueno MG, Rebollo JM, Marin I, Peña G, Bernal E, et al Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331–336.